ERBB2 and breast cancer: Similarly, in breast cancer, A3 activity has been shown to enhance immune infiltration and induce antitumor adaptive immune responses, sensitizing HER2-driven tumors to anti-CTLA-4 checkpoint inhibition (DiMarco et al., 2022).